Dr. Shridar Ganesan
Claim this profileRutgers Cancer Institute of New Jersey
Studies Cancer
Studies Tumors
7 reported clinical trials
42 drugs studied
Area of expertise
1Cancer
KRAS positive
Stage IV
BRAF positive
2Tumors
Stage IV
KRAS positive
Stage III
Affiliated Hospitals
Clinical Trials Shridar Ganesan is currently running
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has an AKT genetic change. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with an AKT genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
Palbociclib + Binimetinib
for Pancreatic Cancer
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Recruiting1 award Phase 210 criteria
More about Shridar Ganesan
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Shridar Ganesan has experience with
- Ipatasertib
- Binimetinib
- Sotorasib
- Paclitaxel
- Palbociclib
- U-13C-glucose
Breakdown of trials Shridar Ganesan has run
Cancer
Tumors
Breast Cancer
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shridar Ganesan specialize in?
Shridar Ganesan focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved KRAS positive patients, or patients who are Stage IV.
Is Shridar Ganesan currently recruiting for clinical trials?
Yes, Shridar Ganesan is currently recruiting for 5 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Shridar Ganesan has studied deeply?
Yes, Shridar Ganesan has studied treatments such as Ipatasertib, Binimetinib, Sotorasib.
What is the best way to schedule an appointment with Shridar Ganesan?
Apply for one of the trials that Shridar Ganesan is conducting.
What is the office address of Shridar Ganesan?
The office of Shridar Ganesan is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.